GlassScriptPhysician profile
Charlotte A Griffith
NPI 1124380761
$2,733.06
in general payments reported to CMS, 2019-2025
28 companies · $660 in 2025
The $660 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $597 · 2022: $417 · 2023: $692 · 2024: $365 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.20 | 2021-2025 | |
| Novo Nordisk INC | $243.14 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $207.96 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $150.90 | 2021-2025 | Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $142.70 | 2021-2025 | Trintellix |
| Glaxosmithkline, LLC. | $131.68 | 2021-2024 | Trelegy Ellipta |
| Amgen INC. | $117.38 | 2023-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.32 | 2023-2024 | Xifaxan |
| Abbott Laboratories | $101.40 | 2021-2024 | Freestyle Libre 3 |
| Lundbeck LLC | $91.86 | 2025 | Rexulti |
| Lilly USA, LLC | $86.03 | 2021-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.54 | 2021-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $72.08 | 2023-2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $66.50 | 2022 | |
| Exact Sciences Corporation | $66.50 | 2023-2024 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $55.09 | 2021 | |
| Corcept Therapeutics | $53.34 | 2023 | Korlym |
| Idorsia Pharmaceuticals US INC | $50.46 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.24 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $38.79 | 2025 | Nexletol |
| Merck Sharp & Dohme LLC | $33.90 | 2025 | Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $31.02 | 2021-2022 | |
| Amarin Pharma, INC. | $29.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.88 | 2024 | |
| Dexcom, INC. | $17.48 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $17.47 | 2021 | |
| Axsome Therapeutics, INC. | $17.20 | 2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlotte Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.